View ValuationThis company is no longer activeThe company may no longer be operating, as it may be out of business. Find out why through their latest events.See Latest EventsPLx Pharma Winddown 将来の成長Future 基準チェック /06現在、 PLx Pharma Winddownの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長23.7%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報Breakeven Date Change • Mar 12No longer forecast to breakevenThe 3 analysts covering PLx Pharma no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$6.50m in 2024. New consensus forecast suggests the company will make a loss of US$21.4m in 2024.すべての更新を表示Recent updatesお知らせ • Oct 19PLx Pharma Winddown Corp. Files Form 15PLx Pharma Winddown Corp. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock under the Securities Exchange Act of 1934, as amended. The par value of the company's common stock was $0.001 per share.お知らせ • Jul 10Plx Pharma Winddown Corp. Announces Executive ChangesPLx Pharma Winddown Corp. on June 30, 2023, the Company terminated the employment of Natasha Giordano, President, and of Rita O’Connor, Head of Manufacturing and Supply Chain. Effective as of July 1, 2023, Ms. O’Connor entered into a consulting arrangement with the Company.Board Change • May 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Member of Scientific Advisory Board Makis Deliargyris was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Feb 14PLx Pharma Receives Written Notice from the Listing Qualifications Department of The Nasdaq Stock Market LLCOn February 7, 2023, PLx Pharma Inc. received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC regarding its noncompliance with Nasdaq Listing Rule 5605(c)(2), which requires, among other things, that the Audit Committee (the Audit Committee") of the Board of Directors of the Company (the Board") be comprised of a minimum of three independent directors. As previously disclosed, John W. Hadden II ceased serving on the Board and its committees as of January 19, 2023, and as a result, the Company's Audit Committee is currently comprised of only two independent directors resulting in the noncompliance. In accordance with Nasdaq Listing Rule 5605(c)(4), the Company is granted a cure period in order to regain compliance with Nasdaq Listing Rule 5605 lasting until the earlier of the Company's next annual stockholders' meeting or January 19, 2024 or, if the next annual stockholders' meeting is held before July 18, 2023, then no later than July 18, 2023. The Company's common stock will continue to be listed and traded on the Nasdaq Capital Market during the compliance period, subject to the Company's compliance with the other continued listing requirements of the Nasdaq Capital Market.お知らせ • Jan 22PLx Pharma Inc. Announces Resignation of John W. Hadden II as Member of BoardOn January 19, 2023, John W. Hadden II, a member of the Board of Directors of PLx Pharma Inc., resigned from the Board effective immediately. Mr. Hadden's resignation is not the result of any disagreement with the Company.お知らせ • Oct 27PLx Pharma Inc. to Report Q3, 2022 Results on Nov 11, 2022PLx Pharma Inc. announced that they will report Q3, 2022 results at 9:30 AM, US Eastern Standard Time on Nov 11, 2022お知らせ • Oct 10PLx Pharma Receives Written Notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC Regarding Minimum Bid Price RequirementOn October 3, 2022, PLx Pharma Inc. ("the Company") received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying it that, for a period of 30 consecutive business days, the bid price of its common stock closed below the minimum of $1.00 per share required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days, or until April 3, 2023, to regain compliance with the minimum bid price requirement. If, at any time during the 180-day compliance period, the closing bid price of the Company's common stock is at least $1.00 per share for a minimum of 10 consecutive business days, the Company will have regained compliance, and Nasdaq will provide the Company with written confirmation of such. If Company fails to regain compliance before April 3, 2023, but meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, the Company may be eligible for additional time to regain compliance with the minimum bid price requirement.お知らせ • Sep 30PLx Pharma Inc., Annual General Meeting, Nov 08, 2022PLx Pharma Inc., Annual General Meeting, Nov 08, 2022, at 09:00 US Eastern Standard Time. Agenda: To elect each of Gary S. Balkema, Kirk Calhoun, Robert Casale, John W. Hadden II, Michael J. Valentino and Natasha Giordano, to serve as directors until the company’s 2023 Annual Meeting of Stockholders and until their successors are duly elected and qualify; to consider an advisory vote on the compensation of company named executive officers as disclosed in the proxy statement; to ratify the appointment of Marcum LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2022; and to transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.お知らせ • Jul 28PLx Pharma Inc. to Report Q2, 2022 Results on Aug 12, 2022PLx Pharma Inc. announced that they will report Q2, 2022 results Pre-Market on Aug 12, 2022お知らせ • Apr 23PLx Pharma Inc. to Report Q1, 2022 Results on May 13, 2022PLx Pharma Inc. announced that they will report Q1, 2022 results Pre-Market on May 13, 2022Recent Insider Transactions • Mar 24Key Executive recently bought €46k worth of stockOn the 15th of March, Rita O'Connor bought around 14k shares on-market at roughly €3.34 per share. This was the largest purchase by an insider in the last 3 months. This was Rita's only on-market trade for the last 12 months.Recent Insider Transactions • Mar 21Key Executive recently bought €46k worth of stockOn the 15th of March, Rita O'Connor bought around 14k shares on-market at roughly €3.34 per share. This was the largest purchase by an insider in the last 3 months. This was Rita's only on-market trade for the last 12 months.Breakeven Date Change • Mar 12No longer forecast to breakevenThe 3 analysts covering PLx Pharma no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$6.50m in 2024. New consensus forecast suggests the company will make a loss of US$21.4m in 2024.お知らせ • Feb 24PLx Pharma Inc. to Report Q4, 2021 Results on Mar 11, 2022PLx Pharma Inc. announced that they will report Q4, 2021 results Pre-Market on Mar 11, 2022お知らせ • Aug 04PLx Pharma Inc.’s VAZALORE to Launch in Nearly 8,000 CVS Stores this MonthPLx Pharma Inc. announced that three stock-keeping units (“SKUs”) of VAZALORE, the first and only U.S. Food and Drug Administration (“FDA”) approved liquid-filled aspirin capsules, will be available in nearly 8,000 CVS stores later this month. CVS, a leading health solutions company, is preparing its retail space with ‘Coming Soon’ placeholders and shelf trays in many of its stores. This includes all three SKUs: VAZALORE 81 mg, 12 count; VAZALORE 81 mg, 30 count; and VAZALORE 325 mg, 30 count. About VAZALORE: VAZALORE is an FDA-approved liquid-filled aspirin capsule that provides patients with vascular disease and diabetic patients who are candidates for aspirin therapy based on physician recommendation, with fast, reliable and predictable platelet inhibition as compared to enteric-coated aspirin. It also reduces the risk of stomach erosions and ulcers, as compared to immediate-release aspirin, common in an acute setting.お知らせ • Jul 20PLx Pharma Inc.’s VAZALORE to Launch in over 8,000 Walgreens Stores Nationwide in AugustPLx Pharma Inc. announced that three stock-keeping units (“SKUs”) of VAZALORE, the first and only U.S. Food and Drug Administration (“FDA”) approved liquid-filled aspirin capsules, will be available in over 8,000 Walgreens stores nationwide later in August. Walgreens has already inserted placeholders to reserve space on shelves for all three SKUs: VAZALORE 81 mg, 12 count; VAZALORE 81 mg, 30 count; and VAZALORE 325 mg, 30 count. VAZALORE is an FDA-approved liquid-filled aspirin capsule that provides patients with vascular disease and diabetic patients who are candidates for aspirin therapy based on physician recommendation, with fast, reliable and predictable platelet inhibition as compared to enteric-coated aspirin. It also reduces the risk of stomach erosions and ulcers, as compared to immediate-release aspirin, common in an acute setting.お知らせ • Jul 15Plx Pharma Inc.’s VAZALORE to Launch in over 4,500 Walmart Stores Nationwide in AugustPLx Pharma Inc. announced that three stock-keeping units (“SKUs”) of VAZALORE, the first and only U.S. Food and Drug Administration (“FDA”) approved liquid-filled aspirin capsules, will be available in over 4,500 Walmart stores across the United States in mid-August. The three SKUs include: VAZALORE 81 mg, 12 count; VAZALORE 81 mg, 30 count; and VAZALORE 325 mg, 30 count.Recent Insider Transactions • Jun 17Executive Chairman recently bought €82k worth of stockOn the 14th of June, Michael Valentino bought around 8k shares on-market at roughly €10.30 per share. This was the largest purchase by an insider in the last 3 months. Michael has been a buyer over the last 12 months, purchasing a net total of €250k worth in shares.Analyst Estimate Surprise Post Earnings • Mar 13Revenue in line with expectationsRevenue was in line with analyst estimates. Over the next year, revenue is expected to shrink by 100% compared to a 3.1% growth forecast for the Pharmaceuticals industry in Germany.Recent Insider Transactions • Mar 10Executive Chairman recently bought €168k worth of stockOn the 5th of March, Michael Valentino bought around 25k shares on-market at roughly €6.72 per share. This was the largest purchase by an insider in the last 3 months. This was Michael's only on-market trade for the last 12 months.お知らせ • Mar 05+ 1 more updatePLx Pharma Inc. has completed a Follow-on Equity Offering in the amount of $63 million.PLx Pharma Inc. has completed a Follow-on Equity Offering in the amount of $63 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 7,875,000 Price\Range: $8 Discount Per Security: $0.48お知らせ • Mar 04PLx Pharma Inc. has completed a Follow-on Equity Offering in the amount of $2.3 million.PLx Pharma Inc. has completed a Follow-on Equity Offering in the amount of $2.3 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offeringお知らせ • Mar 03PLx Pharma Receives FDA Approval of sNDAs for Both Vazalore 325 Mg and 81 MgPLx Pharma Inc. announced that the U.S. Food and Drug Administration (“FDA”) approved supplemental new drug applications (“sNDAs”) for its lead products, VAZALORE™ 325 mg and VAZALORE™ 81 mg (referred to together as “VAZALORE”), the first ever novel, liquid-filled aspirin capsule. In October 2020, the company submitted separate supplemental new drug applications (“sNDAs”) for each dose strength. The submissions were considered chemistry and manufacturing control (“CMC”) filings as they included information on a change in formulation and the new manufacturing site for VAZALORE 325 mg and a new product strength for the 81 mg dose. The submission for the 325 mg dose also contained the results of a clinical study, demonstrating VAZALORE's bioequivalence to immediate-release aspirin, further supporting the change in formulation. The submission for the 81 mg dose builds off the information in the original approved new drug application, as well as the recent sNDA submitted for VAZALORE 325 mg.Is New 90 Day High Low • Feb 11New 90-day high: €6.05The company is up 91% from its price of €3.16 on 13 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 11% over the same period.Is New 90 Day High Low • Dec 23New 90-day high: €5.20The company is up 82% from its price of €2.86 on 24 September 2020. The German market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.お知らせ • Dec 01PLx Pharma Inc. announced that it has received $18.008598 million in funding from White Rock Capital Management, L.P., Level One Partners LLC and other investorsOn November 30, 2020, PLx Pharma Inc. (NasdaqCM:PLXP) closed the transaction. The transaction included participation from 25 investors.お知らせ • Nov 18PLx Pharma Inc. Submits Supplemental New Drug Applications for VAZALORE™ 325 mg and 81 mg to U.S. Food and Drug AdministrationPLx Pharma Inc. announced that two chemistry and manufacturing control (‘CMC’) supplemental New Drug Applications (‘sNDAs’), one for VAZALORE 325 mg and one for VAZALORE 81 mg dose (referred to together as ‘VAZALORE’), were submitted to the U.S. Food and Drug Administration (‘FDA’) in October for regulatory approval. The 325 mg sNDA provided information on a change in formulation and a new manufacturing site for the currently approved VAZALORE and also contains a bioequivalence (‘BE’) clinical study report with the required data and analyses from the recently completed BE study. The submission for the 81 mg dose provided for a new product strength of VAZALORE and builds off the information in the original approved NDA (New Drug Application) and the recent sNDA submitted for VAZALORE 325 mg. The Company received acknowledgement letters from the FDA, officially confirming the receipt of the submissions and setting the estimated completion date for its reviews for VAZALORE 325 mg and VAZALORE 81 mg for the end of February 2021. If approved, the Company plans to bring both doses of VAZALORE to market in the third quarter of 2021. VAZALORE 325 mg is an FDA-approved liquid-filled aspirin capsule that provides patients with vascular disease and diabetic patients who are candidates for aspirin therapy with faster, reliable and more predictable platelet inhibition as compared to enteric-coated aspirin, while also reducing the risk of stomach erosions and ulcers, as compared to immediate-release aspirin, common in an acute setting. PLx’s supplemental New Drug Applications for VAZALORE 325 mg and VAZALORE 81 mg dose strengths, submitted in October 2020 to the U.S. Food and Drug Administration, are currently under regulatory review.お知らせ • Nov 17PLx Pharma Inc. announced that it expects to receive $18.008598 million in funding from White Rock Capital Management, L.P., Level One Partners LLC and other investorsPLx Pharma Inc. (NasdaqCM:PLXP) announced that it has entered into a securities purchase agreement with certain institutional and accredited investors co-led by new investors White Rock Capital Management, L.P. and Level One Partners LLC for private placement of 4,755,373 immediately separable units at a price of $3.787 per unit for gross proceeds of $18,008,597.551 on November 16, 2020. Each unit consists of one common share and 1.1 common share warrant. Each warrant is exercisable at $4.31 per share for a period of 5 years from issuance. The transaction is expected to close on or about November 18, 2020, subject to satisfaction of customary closing conditions. The securities are issued pursuant to exemption provided under Section 4(a)(2) of the Securities Act and Rule 506 of Registration D.Is New 90 Day High Low • Nov 16New 90-day high: €3.58The company is up 27% from its price of €2.82 on 18 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Analyst Estimate Surprise Post Earnings • Nov 15Revenue in line with expectationsRevenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 1,828%, compared to a 2.8% growth forecast for the Pharmaceuticals industry in Germany.お知らせ • Nov 05PLx Pharma Inc. to Report Q3, 2020 Results on Nov 13, 2020PLx Pharma Inc. announced that they will report Q3, 2020 results on Nov 13, 2020お知らせ • Aug 07PLx Pharma Inc. to Report Q2, 2020 Results on Aug 14, 2020PLx Pharma Inc. announced that they will report Q2, 2020 results at 9:00 AM, Eastern Standard Time on Aug 14, 2020お知らせ • Jul 02PLx Pharma Inc.(NasdaqCM:PLXP) dropped from Russell Microcap Value IndexPLx Pharma Inc.(NasdaqCM:PLXP) dropped from Russell Microcap Value Index このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、PLx Pharma Winddown は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測DB:1D5A - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数9/30/20225-28-59-59N/A6/30/202211-41-57-57N/A3/31/202210-48-45-45N/A12/31/20218-49-32-32N/A9/30/20217-61-21-21N/A6/30/20210-43-16-15N/A3/31/20210-30-13-13N/A12/31/20200-17-12-12N/A9/30/20200-11-14-13N/A6/30/20200-6-14-13N/A3/31/20200-10-13-13N/A12/31/20191-34-13-13N/A9/30/20191-29-11-11N/A6/30/20191-34-10-10N/A3/31/20191-28-9-9N/A12/31/201811-10-9N/A9/30/20181-10-14-13N/A6/30/20181-10-14-13N/A3/31/20181-9-16-15N/A12/31/20171-15-14-13N/A9/30/20170-9-8-8N/A6/30/20170-6-7-7N/A3/31/20170-5-3-3N/A12/31/20160-5-2-2N/A9/30/20160-4-2-2N/A6/30/20160-5N/A-2N/A3/31/20160-4N/A-1N/A12/31/20150-4N/A-1N/A9/30/20150-4N/A-2N/A6/30/20150-3N/A-3N/A3/31/20150-4N/A-4N/A12/31/20140-5N/A-5N/A12/31/20131-9N/A-8N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 1D5Aの予測収益成長が 貯蓄率 ( 0.4% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 1D5Aの収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 1D5Aの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 1D5Aの収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 1D5Aの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 1D5Aの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/08/19 04:53終値2023/05/22 00:00収益2022/09/30年間収益2021/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋PLx Pharma Winddown Corp. これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6 アナリスト機関Kenneth TrbovichBrean Capital Historical (Janney Montgomery)Hamed KhorsandBWS Financial Inc.Jason ButlerCitizens JMP Securities, LLC3 その他のアナリストを表示
Breakeven Date Change • Mar 12No longer forecast to breakevenThe 3 analysts covering PLx Pharma no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$6.50m in 2024. New consensus forecast suggests the company will make a loss of US$21.4m in 2024.
お知らせ • Oct 19PLx Pharma Winddown Corp. Files Form 15PLx Pharma Winddown Corp. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock under the Securities Exchange Act of 1934, as amended. The par value of the company's common stock was $0.001 per share.
お知らせ • Jul 10Plx Pharma Winddown Corp. Announces Executive ChangesPLx Pharma Winddown Corp. on June 30, 2023, the Company terminated the employment of Natasha Giordano, President, and of Rita O’Connor, Head of Manufacturing and Supply Chain. Effective as of July 1, 2023, Ms. O’Connor entered into a consulting arrangement with the Company.
Board Change • May 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Member of Scientific Advisory Board Makis Deliargyris was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Feb 14PLx Pharma Receives Written Notice from the Listing Qualifications Department of The Nasdaq Stock Market LLCOn February 7, 2023, PLx Pharma Inc. received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC regarding its noncompliance with Nasdaq Listing Rule 5605(c)(2), which requires, among other things, that the Audit Committee (the Audit Committee") of the Board of Directors of the Company (the Board") be comprised of a minimum of three independent directors. As previously disclosed, John W. Hadden II ceased serving on the Board and its committees as of January 19, 2023, and as a result, the Company's Audit Committee is currently comprised of only two independent directors resulting in the noncompliance. In accordance with Nasdaq Listing Rule 5605(c)(4), the Company is granted a cure period in order to regain compliance with Nasdaq Listing Rule 5605 lasting until the earlier of the Company's next annual stockholders' meeting or January 19, 2024 or, if the next annual stockholders' meeting is held before July 18, 2023, then no later than July 18, 2023. The Company's common stock will continue to be listed and traded on the Nasdaq Capital Market during the compliance period, subject to the Company's compliance with the other continued listing requirements of the Nasdaq Capital Market.
お知らせ • Jan 22PLx Pharma Inc. Announces Resignation of John W. Hadden II as Member of BoardOn January 19, 2023, John W. Hadden II, a member of the Board of Directors of PLx Pharma Inc., resigned from the Board effective immediately. Mr. Hadden's resignation is not the result of any disagreement with the Company.
お知らせ • Oct 27PLx Pharma Inc. to Report Q3, 2022 Results on Nov 11, 2022PLx Pharma Inc. announced that they will report Q3, 2022 results at 9:30 AM, US Eastern Standard Time on Nov 11, 2022
お知らせ • Oct 10PLx Pharma Receives Written Notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC Regarding Minimum Bid Price RequirementOn October 3, 2022, PLx Pharma Inc. ("the Company") received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying it that, for a period of 30 consecutive business days, the bid price of its common stock closed below the minimum of $1.00 per share required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days, or until April 3, 2023, to regain compliance with the minimum bid price requirement. If, at any time during the 180-day compliance period, the closing bid price of the Company's common stock is at least $1.00 per share for a minimum of 10 consecutive business days, the Company will have regained compliance, and Nasdaq will provide the Company with written confirmation of such. If Company fails to regain compliance before April 3, 2023, but meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, the Company may be eligible for additional time to regain compliance with the minimum bid price requirement.
お知らせ • Sep 30PLx Pharma Inc., Annual General Meeting, Nov 08, 2022PLx Pharma Inc., Annual General Meeting, Nov 08, 2022, at 09:00 US Eastern Standard Time. Agenda: To elect each of Gary S. Balkema, Kirk Calhoun, Robert Casale, John W. Hadden II, Michael J. Valentino and Natasha Giordano, to serve as directors until the company’s 2023 Annual Meeting of Stockholders and until their successors are duly elected and qualify; to consider an advisory vote on the compensation of company named executive officers as disclosed in the proxy statement; to ratify the appointment of Marcum LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2022; and to transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
お知らせ • Jul 28PLx Pharma Inc. to Report Q2, 2022 Results on Aug 12, 2022PLx Pharma Inc. announced that they will report Q2, 2022 results Pre-Market on Aug 12, 2022
お知らせ • Apr 23PLx Pharma Inc. to Report Q1, 2022 Results on May 13, 2022PLx Pharma Inc. announced that they will report Q1, 2022 results Pre-Market on May 13, 2022
Recent Insider Transactions • Mar 24Key Executive recently bought €46k worth of stockOn the 15th of March, Rita O'Connor bought around 14k shares on-market at roughly €3.34 per share. This was the largest purchase by an insider in the last 3 months. This was Rita's only on-market trade for the last 12 months.
Recent Insider Transactions • Mar 21Key Executive recently bought €46k worth of stockOn the 15th of March, Rita O'Connor bought around 14k shares on-market at roughly €3.34 per share. This was the largest purchase by an insider in the last 3 months. This was Rita's only on-market trade for the last 12 months.
Breakeven Date Change • Mar 12No longer forecast to breakevenThe 3 analysts covering PLx Pharma no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$6.50m in 2024. New consensus forecast suggests the company will make a loss of US$21.4m in 2024.
お知らせ • Feb 24PLx Pharma Inc. to Report Q4, 2021 Results on Mar 11, 2022PLx Pharma Inc. announced that they will report Q4, 2021 results Pre-Market on Mar 11, 2022
お知らせ • Aug 04PLx Pharma Inc.’s VAZALORE to Launch in Nearly 8,000 CVS Stores this MonthPLx Pharma Inc. announced that three stock-keeping units (“SKUs”) of VAZALORE, the first and only U.S. Food and Drug Administration (“FDA”) approved liquid-filled aspirin capsules, will be available in nearly 8,000 CVS stores later this month. CVS, a leading health solutions company, is preparing its retail space with ‘Coming Soon’ placeholders and shelf trays in many of its stores. This includes all three SKUs: VAZALORE 81 mg, 12 count; VAZALORE 81 mg, 30 count; and VAZALORE 325 mg, 30 count. About VAZALORE: VAZALORE is an FDA-approved liquid-filled aspirin capsule that provides patients with vascular disease and diabetic patients who are candidates for aspirin therapy based on physician recommendation, with fast, reliable and predictable platelet inhibition as compared to enteric-coated aspirin. It also reduces the risk of stomach erosions and ulcers, as compared to immediate-release aspirin, common in an acute setting.
お知らせ • Jul 20PLx Pharma Inc.’s VAZALORE to Launch in over 8,000 Walgreens Stores Nationwide in AugustPLx Pharma Inc. announced that three stock-keeping units (“SKUs”) of VAZALORE, the first and only U.S. Food and Drug Administration (“FDA”) approved liquid-filled aspirin capsules, will be available in over 8,000 Walgreens stores nationwide later in August. Walgreens has already inserted placeholders to reserve space on shelves for all three SKUs: VAZALORE 81 mg, 12 count; VAZALORE 81 mg, 30 count; and VAZALORE 325 mg, 30 count. VAZALORE is an FDA-approved liquid-filled aspirin capsule that provides patients with vascular disease and diabetic patients who are candidates for aspirin therapy based on physician recommendation, with fast, reliable and predictable platelet inhibition as compared to enteric-coated aspirin. It also reduces the risk of stomach erosions and ulcers, as compared to immediate-release aspirin, common in an acute setting.
お知らせ • Jul 15Plx Pharma Inc.’s VAZALORE to Launch in over 4,500 Walmart Stores Nationwide in AugustPLx Pharma Inc. announced that three stock-keeping units (“SKUs”) of VAZALORE, the first and only U.S. Food and Drug Administration (“FDA”) approved liquid-filled aspirin capsules, will be available in over 4,500 Walmart stores across the United States in mid-August. The three SKUs include: VAZALORE 81 mg, 12 count; VAZALORE 81 mg, 30 count; and VAZALORE 325 mg, 30 count.
Recent Insider Transactions • Jun 17Executive Chairman recently bought €82k worth of stockOn the 14th of June, Michael Valentino bought around 8k shares on-market at roughly €10.30 per share. This was the largest purchase by an insider in the last 3 months. Michael has been a buyer over the last 12 months, purchasing a net total of €250k worth in shares.
Analyst Estimate Surprise Post Earnings • Mar 13Revenue in line with expectationsRevenue was in line with analyst estimates. Over the next year, revenue is expected to shrink by 100% compared to a 3.1% growth forecast for the Pharmaceuticals industry in Germany.
Recent Insider Transactions • Mar 10Executive Chairman recently bought €168k worth of stockOn the 5th of March, Michael Valentino bought around 25k shares on-market at roughly €6.72 per share. This was the largest purchase by an insider in the last 3 months. This was Michael's only on-market trade for the last 12 months.
お知らせ • Mar 05+ 1 more updatePLx Pharma Inc. has completed a Follow-on Equity Offering in the amount of $63 million.PLx Pharma Inc. has completed a Follow-on Equity Offering in the amount of $63 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 7,875,000 Price\Range: $8 Discount Per Security: $0.48
お知らせ • Mar 04PLx Pharma Inc. has completed a Follow-on Equity Offering in the amount of $2.3 million.PLx Pharma Inc. has completed a Follow-on Equity Offering in the amount of $2.3 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
お知らせ • Mar 03PLx Pharma Receives FDA Approval of sNDAs for Both Vazalore 325 Mg and 81 MgPLx Pharma Inc. announced that the U.S. Food and Drug Administration (“FDA”) approved supplemental new drug applications (“sNDAs”) for its lead products, VAZALORE™ 325 mg and VAZALORE™ 81 mg (referred to together as “VAZALORE”), the first ever novel, liquid-filled aspirin capsule. In October 2020, the company submitted separate supplemental new drug applications (“sNDAs”) for each dose strength. The submissions were considered chemistry and manufacturing control (“CMC”) filings as they included information on a change in formulation and the new manufacturing site for VAZALORE 325 mg and a new product strength for the 81 mg dose. The submission for the 325 mg dose also contained the results of a clinical study, demonstrating VAZALORE's bioequivalence to immediate-release aspirin, further supporting the change in formulation. The submission for the 81 mg dose builds off the information in the original approved new drug application, as well as the recent sNDA submitted for VAZALORE 325 mg.
Is New 90 Day High Low • Feb 11New 90-day high: €6.05The company is up 91% from its price of €3.16 on 13 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 11% over the same period.
Is New 90 Day High Low • Dec 23New 90-day high: €5.20The company is up 82% from its price of €2.86 on 24 September 2020. The German market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
お知らせ • Dec 01PLx Pharma Inc. announced that it has received $18.008598 million in funding from White Rock Capital Management, L.P., Level One Partners LLC and other investorsOn November 30, 2020, PLx Pharma Inc. (NasdaqCM:PLXP) closed the transaction. The transaction included participation from 25 investors.
お知らせ • Nov 18PLx Pharma Inc. Submits Supplemental New Drug Applications for VAZALORE™ 325 mg and 81 mg to U.S. Food and Drug AdministrationPLx Pharma Inc. announced that two chemistry and manufacturing control (‘CMC’) supplemental New Drug Applications (‘sNDAs’), one for VAZALORE 325 mg and one for VAZALORE 81 mg dose (referred to together as ‘VAZALORE’), were submitted to the U.S. Food and Drug Administration (‘FDA’) in October for regulatory approval. The 325 mg sNDA provided information on a change in formulation and a new manufacturing site for the currently approved VAZALORE and also contains a bioequivalence (‘BE’) clinical study report with the required data and analyses from the recently completed BE study. The submission for the 81 mg dose provided for a new product strength of VAZALORE and builds off the information in the original approved NDA (New Drug Application) and the recent sNDA submitted for VAZALORE 325 mg. The Company received acknowledgement letters from the FDA, officially confirming the receipt of the submissions and setting the estimated completion date for its reviews for VAZALORE 325 mg and VAZALORE 81 mg for the end of February 2021. If approved, the Company plans to bring both doses of VAZALORE to market in the third quarter of 2021. VAZALORE 325 mg is an FDA-approved liquid-filled aspirin capsule that provides patients with vascular disease and diabetic patients who are candidates for aspirin therapy with faster, reliable and more predictable platelet inhibition as compared to enteric-coated aspirin, while also reducing the risk of stomach erosions and ulcers, as compared to immediate-release aspirin, common in an acute setting. PLx’s supplemental New Drug Applications for VAZALORE 325 mg and VAZALORE 81 mg dose strengths, submitted in October 2020 to the U.S. Food and Drug Administration, are currently under regulatory review.
お知らせ • Nov 17PLx Pharma Inc. announced that it expects to receive $18.008598 million in funding from White Rock Capital Management, L.P., Level One Partners LLC and other investorsPLx Pharma Inc. (NasdaqCM:PLXP) announced that it has entered into a securities purchase agreement with certain institutional and accredited investors co-led by new investors White Rock Capital Management, L.P. and Level One Partners LLC for private placement of 4,755,373 immediately separable units at a price of $3.787 per unit for gross proceeds of $18,008,597.551 on November 16, 2020. Each unit consists of one common share and 1.1 common share warrant. Each warrant is exercisable at $4.31 per share for a period of 5 years from issuance. The transaction is expected to close on or about November 18, 2020, subject to satisfaction of customary closing conditions. The securities are issued pursuant to exemption provided under Section 4(a)(2) of the Securities Act and Rule 506 of Registration D.
Is New 90 Day High Low • Nov 16New 90-day high: €3.58The company is up 27% from its price of €2.82 on 18 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Analyst Estimate Surprise Post Earnings • Nov 15Revenue in line with expectationsRevenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 1,828%, compared to a 2.8% growth forecast for the Pharmaceuticals industry in Germany.
お知らせ • Nov 05PLx Pharma Inc. to Report Q3, 2020 Results on Nov 13, 2020PLx Pharma Inc. announced that they will report Q3, 2020 results on Nov 13, 2020
お知らせ • Aug 07PLx Pharma Inc. to Report Q2, 2020 Results on Aug 14, 2020PLx Pharma Inc. announced that they will report Q2, 2020 results at 9:00 AM, Eastern Standard Time on Aug 14, 2020
お知らせ • Jul 02PLx Pharma Inc.(NasdaqCM:PLXP) dropped from Russell Microcap Value IndexPLx Pharma Inc.(NasdaqCM:PLXP) dropped from Russell Microcap Value Index